Research programme: thrombosis therapy - APT Therapeutics

Drug Profile

Research programme: thrombosis therapy - APT Therapeutics

Alternative Names: APT 102; APT 301; APT 302; APT 502

Latest Information Update: 05 Jan 2017

Price : $50

At a glance

  • Originator APT Therapeutics
  • Developer APT Therapeutics; Washington University School of Medicine
  • Class Enzymes; Recombinant proteins
  • Mechanism of Action Platelet activating factor inhibitors; Platelet aggregation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Myocardial infarction; Stroke

Highest Development Phases

  • Preclinical Stroke; Thrombosis
  • No development reported Cancer metastases

Most Recent Events

  • 03 Jan 2017 APT Therapeutics and AstraZeneca enter research and option collaboration for development of APT 102
  • 21 Nov 2014 No development reported - Preclinical for Cancer metastases in USA (IV)
  • 14 Oct 2014 Research programme: thrombosis therapy - APT Therapeutics is available for licensing as of 02 Oct 2014
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top